The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.
 
Jonathan R. Strosberg
No Relationships to Disclose
 
Edward M. Wolin
No Relationships to Disclose
 
Beth Chasen
No Relationships to Disclose
 
Matthew H. Kulke
Consulting or Advisory Role - Ipsen; Novartis
 
David L Bushnell
No Relationships to Disclose
 
Martyn E. Caplin
No Relationships to Disclose
 
Richard P. Baum
No Relationships to Disclose
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Guardant Health; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications; Genentech/Roche; Lexicon; Merck; Merrimack; Novartis; Pharm-Olam
 
Timothy J. Hobday
No Relationships to Disclose
 
Andrew Eugene Hendifar
No Relationships to Disclose
 
Kjell E. Oberg
No Relationships to Disclose
 
Maribel Lopera Sierra
No Relationships to Disclose
 
Dik J. Kwekkeboom
No Relationships to Disclose
 
Philippe B. Ruszniewski
No Relationships to Disclose
 
Eric Krenning
No Relationships to Disclose